OBJECTIVE: To report a case of a patient treated with an angiotensin-conver
ting enzyme (ACE) inhibitor with a good neonatal outcome.
CASE REPORT: A 39-year-old African-Caribbean patient who had chronic hypert
ension presented at 18 weeks' gestation with acute hypertension. She was be
ing treated for chronic hypertension with lisinopril, but had self-disconti
nued treatment. Attempts to control her hypertension with labetolol, nifedi
pine, and methyldopa were ineffective, She was therefore offered terminatio
n of pregnancy so,treatment with lisinopril co;ld be restarted. The patient
elected to continue with the pregnancy in spite of the fetal risks associa
ted with the use of an ACE inhibitor. She was delivered of a girl at 26 wee
ks' gestation. The baby initially had renal failure and also developed acut
e necrotizing enterocolitis, The renal failure improved simultaneously with
the latter complication, and it is postulated that there was enteric excre
tion of lisinopril. The baby was discharged home on day 102 with no further
complications.
DISCUSSION: ACE inhibitors are acceptable medications to use in the first t
rimester of pregnancy; however, fetal malformations and neonatal complicati
ons have been associated with their use later in pregnancy, and they have a
perinatal mortality rate of 97/1000. Lisinopril is excreted in urine and f
eces unchanged, and its half-life is prolonged in anuric neonates. Peritone
al dialysis eliminates lisinopril; however, this neonate improved after tre
atment for necrotizing enterocolitis and simultaneous improvement in bower
function.
CONCLUSIONS: ACE inhibitors should not be used in pregnancy beyond the end
of the first trimester, In exceptional cases, they may be indicated for the
control of severe hypertension when the patient is refractory to other med
ications. The patient should be fully counseled about the adverse effect pr
ofile and neonatal outcome, This case report documents a successful outcome
for mother and baby in these circumstances.